Skip to main content
. 2021 Jun 3;17:17448069211021698. doi: 10.1177/17448069211021698

Figure 4.

Figure 4.

No significant effect of NB001 on anxiety-like behavior, locomotor activity, fear memory, and motor function. (a) Representative traces showing the movement of saline- and NB001-injected (10 mg/kg) mice in the EPM for 5 min. (b) There was no significant difference in the number of arm entries (open and closed) between saline-injected (n = 5) and NB001-injected (n = 7) mice. (c) There was no significant difference in the percentage of time spent in the open arms between saline- and NB001-injected mice. (d) Representative traces showing the movement of saline-injected (n = 6) and NB001-injected (n = 6) mice in the open field for 30 min. (e-f) Saline- and NB001-treated mice showed no difference in the open field test. (g) There was no significant difference in latency to fall between saline-injected (n = 5) and NB001-injected (n = 6) mice. In each experiment, mice were given an oral injection of NB001 (10 mg/kg) or saline 30 min before the test. (h) There was no significant difference in fear memory tests (n=6).